4 Reasons Valeant Pharmaceuticals Intl Inc. Might Be a Good Investment Today

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is down over 20% in the past month and could present a great buying opportunity.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has seen its stock go on a rough ride with a drop of over 58% in the past year. Year to date, the stock has declined by 15%. There is no shortage of bad news and pessimism around the company, but for opportunistic investors that are not afraid of risk, fear can create significant opportunities.

I will give you four reasons why the stock could be a very good buy today.

The company’s bottom line has been showing improvements of late

Although Valeant didn’t achieve any sales growth, it was able to improve its bottom line. In the previous year, the company posted $2.4 billion in sales for its second quarter, and it incurred a loss of $302 million, while this year saw a 7% year-over-year decline in revenue but a net loss of just $38 million. The company also posted a strong first quarter with profit of $628 million.

Debt levels have been coming down

The company has also made strides to bring down its debt levels. A year ago, the company had non-current liabilities of over $38 billion which have since dropped to $33 billion for an improvement of over 12%.

Cash flows are strong and improving

Since Valeant has a great deal of amortization, its cash flow is going to be better than its net income, which is evident by the company’s positive cash flow from operations in each of its past five quarters. In the past 12 months, Valeant has seen its free cash flow total $1.9 billion, and if the company can continue that pace, it would show an improvement over last year’s free cash of just under $1.8 billion.

The stock price may have found a bottom and could be on the way up

Outside of a few months from mid-March to early May, when the stock dropped below $15 a share, the share price has been able to see support at that price point. Although the past month has seen the stock price drop by over 21%, since early May, the share has been in a range of $16-22 with no sign of a significant trend in one direction or the other. The company’s next earnings are not due until November, so unless some significant news comes out before then, I would expect a bit of stability from the share price until then.

The Relative Strength Index (RSI) indicator, which tracks average price gains and losses over a period of time, is currently at a level of 31 for the past 14 days, and a number of less than 30 indicates the stock has been oversold and could be due for a price reversal. The last time the stock reached under 30 was when it hit its 52-week low of $11.20, and at that time the RSI was just over 26.

Bottom line

Valeant isn’t a stock for the risk-averse investors, but it could present a good opportunity, at least in the short term, to take advantage of a stock that has been on a steep decline. There are certainly no guarantees it can’t go lower, but the evidence suggests the share price should be more stable going forward. The long-term growth of the share price will ultimately depend on the company’s ability to build on the positive results from its first two quarters in 2017 and its ability to convince investors that it is getting its house in order.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Canadian Dollars
Stock Market

Where to Invest $5,000 in April 2024

Do you have some extra cash to spare? Here are five companies to invest $5,000 in next month.

Read more »

Plane on runway, aircraft
Stocks for Beginners

Up 53% From its 52-Week Low, Is Cargojet Stock Still a Buy?

Cargojet (TSX:CJT) stock is up a whopping 53%, nearing closer to 52-week highs from 52-week lows, so what's next for…

Read more »

Question marks in a pile
Bank Stocks

Should You Buy Canadian Western Bank for its 4.8% Dividend Yield?

Down 35% from all-time highs, Canadian Western Bank offers a tasty dividend yield of 4.8%. Is the TSX bank stock…

Read more »

Gold bars
Metals and Mining Stocks

Why Alamos Gold Jumped 7% on Wednesday

Alamos (TSX:AGI) stock and Argonaut Gold (TSX:AR) surged after the companies announced a friendly acquisition for $325 million.

Read more »

tsx today
Stock Market

TSX Today: Why Record-Breaking Rally Could Extend on Thursday, March 28

The main TSX index closed above the 22,000 level for the first time yesterday and remains on track to post…

Read more »

Nuclear power station cooling tower
Metals and Mining Stocks

If You’d Invested $1,000 in Cameco Stock 5 Years Ago, This Is How Much You’d Have Now

Cameco (TSX:CCO) stock still looks undervalued, despite a 258% rally. Can the uranium miner deliver more capital gains to shareholders?

Read more »

Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept
Dividend Stocks

TFSA Magic: Earn Enormous Passive Income That the CRA Can’t Touch

If you're seeking out passive income, with zero taxes involved, then get on board with a TFSA and this portfolio…

Read more »

potted green plant grows up in arrow shape
Stocks for Beginners

3 Growth Stocks I’m Buying in April

These three growth stocks are up in the last year, and that is likely to continue on as we keep…

Read more »